Estats Units - anglès - NLM (National Library of Medicine)

upsher-smith laboratories, llc - valproic acid (unii: 614oi1z5wi) (valproic acid - unii:614oi1z5wi) - valproic acid 250 mg - valproic acid capsules are indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. valproic acid capsules are indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. complex absence is the term used when other signs are also present. see warnings and precautions (5.1) for statement regarding fatal hepatic dysfunction. because of the risk to the fetus of decreased iq, neurodevelopmental disorders, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women with epilepsy or b

Estats Units - anglès - NLM (National Library of Medicine)

upsher-smith laboratories, inc. - chlorpromazine hydrochloride (unii: 9wp59609j6) (chlorpromazine - unii:u42b7vya4p) - chlorpromazine hydrochloride 10 mg - for the management of manifestations of psychotic disorders. for the treatment of schizophrenia. to control nausea and vomiting. for relief of restlessness and apprehension before surgery. for acute intermittent porphyria. as an adjunct in the treatment of tetanus. to control the manifestations of the manic type of manic-depressive illness. for relief of intractable hiccups. for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance. do not use in patients with known hypersensitivity to phenothiazines. do not use in comatose states or in the presence of large amounts of central nervo

Estats Units - anglès - NLM (National Library of Medicine)

upsher-smith laboratories, llc - benazepril hydrochloride (unii: n1sn99t69t) (benazeprilat - unii:jrm708l703), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - benazepril hydrochloride 10 mg - benazepril hydrochloride and hydrochlorothiazide tablets are indicated for the treatment of hypertension. this fixed combination drug is not indicated for the initial therapy of hypertension (see dosage and administration). benazepril hydrochloride and hydrochlorothiazide is contraindicated in patients who are anuric. benazepril hydrochloride and hydrochlorothiazide is also contraindicated in patients who are hypersensitive to benazepril, to any other ace inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. hypersensitivity reactions are more likely to occur in patients with a history of allergy or bronchial asthma. benazepril hydrochloride and hydrochlorothiazide is also contraindicated in patients with a history of angioedema with or without previous ace inhibitor treatment. benazepril hydrochloride and hydrochlorothiazide is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer benazepril hydrochloride and hydrochlorothiazide within 36 hours o

Estats Units - anglès - NLM (National Library of Medicine)

newton laboratories, inc. - bismuth (unii: u015tt5i8h) (bismuth - unii:u015tt5i8h), aloe (unii: v5vd430yw9) (aloe - unii:v5vd430yw9), angelica sinensis root (unii: b66f4574ug) (angelica sinensis root - unii:b66f4574ug), antimony trisulfide (unii: f79059a38u) (antimony trisulfide - unii:f79059a38u), silver nitrate (unii: 95it3w8jze) (silver cation - unii:57n7b0k90a), arnica montana (unii: o80ty208zw) (arnica montana - unii:o80ty208zw), arsenic trioxide (unii: s7v92p67ho) (arsenic cation (3+) - unii:c96613f5av), baptisia tinctoria (unii - bismuth 15 [hp_x] in 1 ml - tummy upset   formulated for symptoms associated with digestive discomfort such as nausea, "spitting up", vomiting, cramping, pain and gas. formulated for symptoms associated with digestive discomfort such as nausea,"spitting up", vomiting, cramping, pain and gas.

Estats Units - anglès - NLM (National Library of Medicine)

upsher-smith laboratories, llc - nystatin (unii: bdf1o1c72e) (nystatin - unii:bdf1o1c72e) - nystatin 100000 [usp'u] in 1 g - nyamyc® (nystatin topical powder, usp) is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by candida albicans and other susceptible candida species. nyamyc® (nystatin topical powder, usp) is not indicated for systemic, oral, intravaginal or ophthalmic use. nyamyc® (nystatin topical powder, usp) is contraindicated in patients with a history of hypersensitivity to any of its components.

Estats Units - anglès - NLM (National Library of Medicine)

newton laboratories, inc. - bismuth (unii: u015tt5i8h) (bismuth - unii:u015tt5i8h), aloe (unii: v5vd430yw9) (aloe - unii:v5vd430yw9), angelica sinensis root (unii: b66f4574ug) (angelica sinensis root - unii:b66f4574ug), antimony trisulfide (unii: f79059a38u) (antimony trisulfide - unii:f79059a38u), silver nitrate (unii: 95it3w8jze) (silver cation - unii:57n7b0k90a), arnica montana (unii: o80ty208zw) (arnica montana - unii:o80ty208zw), arsenic trioxide (unii: s7v92p67ho) (arsenic cation (3+) - unii:c96613f5av), baptisia tinctori - bismuth 15 [hp_x] in 1 g - tummy upset   formulated for symptoms associated with digestive discomfort such as nausea, "spitting up", vomiting, cramping, pain and gas. formulated for symptoms associated with digestive discomfort such as nausea,"spitting up", vomiting, cramping, pain and gas.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - diphtheria crm197 protein, quantity: 16.7 microgram; meningococcal oligosaccharide group a, quantity: 10 microgram - injection, powder for - excipient ingredients: sucrose; monobasic potassium phosphate - menveo is indicated for active immunisation of infants and children (from 2 months of age), adolescents and adults to prevent invasive disease caused by neisseria meningitidis serogroups a, c, w-135 and y. the use of this vaccine should be in accordance with official recommendations.

Estats Units - anglès - NLM (National Library of Medicine)

upsher-smith laboratories, llc - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride 600 mg - because of reports of intestinal and gastric ulceration and bleeding with controlled-release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for patients in whom there is a problem of compliance with these preparations. - for the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. - for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, and certain diarrheal

Estats Units - anglès - NLM (National Library of Medicine)

upsher-smith laboratories, llc - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride 600 mg - because of reports of intestinal and gastric ulceration and bleeding with controlled-release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for patients in whom there is a problem of compliance with these preparations. - for the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. - for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, and certain diarrheal s

Estats Units - anglès - NLM (National Library of Medicine)

upsher-smith laboratories, llc - oxandrolone (unii: 7h6tm3ct4l) (oxandrolone - unii:7h6tm3ct4l) - oxandrolone 10 mg - oxandrolone tablets, usp are indicated as adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma, and in some patients who without definite pathophysiologic reasons fail to gain or to maintain normal weight, to offset the protein catabolism associated with prolonged administration of corticosteroids, and for the relief of the bone pain frequently accompanying osteoporosis (see dosage and administration ). oxandrolone is classified as a controlled substance under the anabolic steroids control act of 1990 and has been assigned to schedule iii (non-narcotic). - known or suspected carcinoma of the prostate or the male breast. - carcinoma of the breast in females with hypercalcemia (androgenic anabolic steroids may stimulate osteolytic bone resorption). - pregnancy, because of possible masculinization of the fetus. oxandrolone has been shown to cause embryotoxicity, fetotoxicity, infertility, and masculinization of female animal offspring when